166953-02-2

Upstream product

• 7536-58-5 BOC-L-aspartic acid 4-benzyl ester 
• 4530-20-5 BOC-glycine 

Downstream Products

• 110697-46-6 H-Arg-Gly-Asp-Phe-OH 
• 906674-58-6 estrone-3-oxyacetyl-Arg(NO₂)-Gly-Asp(OBzl)-Phe-OBzl 
• 906673-91-4 estradiol-3-O-acetyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 906673-85-6 estradiol-17β-O-4-oxobutanoyl-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 
• 906673-81-2 Boc-Arg(Nω-NO2)-Gly-Asp(OBn)-Phe-OBn 

Relevant academic research and scientific papers

Improved anti-osteoporosis potency and reduced endometrial membrane hyperplasia during hormone replacement therapy with estrogen-RGD peptide conjugates

To improve the specificity and potency of estrogen replacement therapy therapeutics while also minimizing the side effects such as bone resorption and thickening of the uterine wall, a series of novel estrogen-derived conjugates estradiol-3-RGD, estradiol

NOVEL COMPOUND WITH EFFECTS OF THROMBOLYSIS, FREE RADICAL SCAVENGING AND THROMBUS-TARGETING AS WELL AS PREPARATION METHOD AND USE THEREOF

The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.